Interview with the CEO, CFO & President: Bio-Path Holdings, Inc. (NASDAQ:BPTH)
Peter Nielsen is President, Chief Executive Officer and Chief Financial Officer of Bio-Path Holdings, Inc. Mr. Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, and currently serves as Bio-Path’s President, Chief Executive Officer, Chief Financial Officer and Chairman of the board of directors. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from the University of Texas MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path’s lead product, prexigebersen — BP1001. Over the next 10 years, Mr. Nielsen led the clinical advancement of BP1001 into Phase II studies, the introduction of additional pipeline candidates and the company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He currently serves as a director of Bio-Path. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He has earned degrees in engineering, mathematics and an MBA in finance from the University of California at Berkeley. Profile
TWST: Would you start by providing a brief overview of the company and a description of its core technology?